



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 45225

Title: Harnessing the potential of gene editing technology using CRISPR in inflammatory bowel disease

Reviewer's code: 00051373

Reviewer's country: Taiwan

Science editor: Jia-Ping Yan

Reviewer accepted review: 2019-02-06 06:15

Reviewer performed review: 2019-02-06 07:25

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer's expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Minor revision	<input checked="" type="checkbox"/> Advanced
		<input checked="" type="checkbox"/> Major revision	<input type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The current manuscript is look like a mini-review but not so-called to be an editorial. This is a hot topic to describe the CRISPR/Cas9 to explore the genes editing in inflammatory bowel disease. The current manuscript is poor preparation on the



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

references citation. All of the references need to be cited from 1 to 42 on the text. At the same time, missing references citation such as 2, 3, 5, 10, 16, 17, 18, 19, 20, 21, 22, 31, 43, 44 in the body of manuscript and lacking of references 43, 44, 45 and 46 in the section of reference. It should not be accepted with the current status.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 45225

Title: Harnessing the potential of gene editing technology using CRISPR in inflammatory bowel disease

Reviewer’s code: 00182114

Reviewer’s country: Japan

Science editor: Jia-Ping Yan

Reviewer accepted review: 2019-02-07 06:40

Reviewer performed review: 2019-02-07 11:53

Review time: 5 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good		<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer’s expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Minor revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Major revision	<input type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

When reading about inflammatory bowel diseases, it is important to know that Crohn’s disease is not the same thing as ulcerative colitis, another type of IBD. The symptoms of these two illnesses are quite similar, but the areas affected in the gastrointestinal tract (GI



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

tract) are different. Crohn's most commonly affects the end of the small bowel (the ileum) and the beginning of the colon, but it may affect any part of the gastrointestinal (GI) tract, from the mouth to the anus. Ulcerative colitis is limited to the colon, also called the large intestine. Crohn's disease can also affect the entire thickness of the bowel wall, while ulcerative colitis only involves the innermost lining of the colon. Finally, in Crohn's disease, the inflammation of the intestine can "skip"-- leaving normal areas in between patches of diseased intestine. In ulcerative colitis this does not occur. I ask question to author. 1. Please tell me the etiology which CRISPR/Cas9 cause good effect for UC and CD. 2. What kind of stage of UC and CD will be suitable for CRISPR/Cas9 therapy?

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 45225

Title: Harnessing the potential of gene editing technology using CRISPR in inflammatory bowel disease

Reviewer's code: 00058381

Reviewer's country: Austria

Science editor: Jia-Ping Yan

Reviewer accepted review: 2019-02-07 08:44

Reviewer performed review: 2019-02-12 12:15

Review time: 5 Days and 3 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This manuscript provides an overview on a current topic, including a discussion of limitations. Please check the correct spelling of medical terms; e.g., "Streptococcus pyogenies" -> Streptococcus pyogenes (Introduction, paragraph 4), "Interleuking 12" ->



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Interleukin 12 (Legend for Table 1). Language polishing is recommended; e.g., "Quickly evolving advancement of DNA engineering such as CRISPR technology and its exponential use in diseases such as sickle cell or HIV resistance in human embryos may suggest that its optimal time to further our understanding of IBD pathogenesis and treatment (Introduction, paragraph 5)"; "The deaminase region can be altered so that it mutates specific DNA bases, ie: C to T, or introduce a 'stop' codon in a specific place" ("Current Status"); "This allowed researchers to wipe out gene's function and determine what gene is implicated in disease, but it's been difficult to fix a 'point mutations', which are majority of disease-associated human genetic variants" ("Limitations"); etc.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No